GSS Stock Overview
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Genetic Signatures Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.97 |
| 52 Week High | AU$1.40 |
| 52 Week Low | AU$0.63 |
| Beta | 0.19 |
| 1 Month Change | 9.60% |
| 3 Month Change | 37.59% |
| 1 Year Change | -22.40% |
| 3 Year Change | -16.38% |
| 5 Year Change | 193.94% |
| Change since IPO | 100.00% |
Recent News & Updates
Recent updates
Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected
Oct 10
One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates
Jun 29Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Feb 28AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results
Feb 25What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?
Feb 07
What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?
Jan 17Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth
Dec 27Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business
Dec 06Shareholder Returns
| GSS | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 0% | 0.2% | 0.6% |
| 1Y | -22.4% | -48.0% | 3.5% |
Return vs Industry: GSS exceeded the Australian Life Sciences industry which returned -48% over the past year.
Return vs Market: GSS underperformed the Australian Market which returned 3.5% over the past year.
Price Volatility
| GSS volatility | |
|---|---|
| GSS Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 9.1% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 15.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: GSS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: GSS's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | John Melki | https://www.geneticsignatures.com |
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in Australia, the Asia Pacific, the Americas, Europe, the Middle East, Israel, and Africa. It designs and manufactures a suite of real-time polymerase chain reaction-based products for detection of infectious diseases under the EasyScreen brand name. The company also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens.
Genetic Signatures Limited Fundamentals Summary
| GSS fundamental statistics | |
|---|---|
| Market Cap | AU$139.11m |
| Earnings (TTM) | AU$3.06m |
| Revenue (TTM) | AU$35.50m |
45.4x
P/E Ratio3.9x
P/S RatioIs GSS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GSS income statement (TTM) | |
|---|---|
| Revenue | AU$35.50m |
| Cost of Revenue | AU$13.60m |
| Gross Profit | AU$21.90m |
| Other Expenses | AU$18.84m |
| Earnings | AU$3.06m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.021 |
| Gross Margin | 61.69% |
| Net Profit Margin | 8.63% |
| Debt/Equity Ratio | 0% |
How did GSS perform over the long term?
See historical performance and comparison